Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There have been significant improvements in the diagnosis and treatment of colorectal cancer over the past 15 years. However, some 30% of patients with colorectal cancer have disseminated disease at presentation, and furthermore, 50% of patients initially believed to be cured by surgery subsequently relapse and die of the disease. Novel treatment concepts based on understanding the molecular signatures that separate tumor from normal epithelium, such as immunotherapy, are aimed at abolishing microscopic residual disease post standard treatment. The authors provide an overview of progress in the development of specific and nonspecific immunotherapies and explain why definition of end-points and early translation of immunotherapy into the adjuvant field are key to effective use of such agents in the clinical setting.

Original publication

DOI

10.1586/14737140.3.1.63

Type

Journal article

Journal

Expert Rev Anticancer Ther

Publication Date

02/2003

Volume

3

Pages

63 - 78

Keywords

Animals, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Neoplasm, Cancer Vaccines, Colorectal Neoplasms, Dendritic Cells, Humans, Immunity, Cellular, Immunotherapy, Immunotherapy, Adoptive, Peptides, Polynucleotides, Vaccination